Bulletin of Reproductive Health

The scientific peer-rewieved medical journal "Bulletin of Reproductive Health" is issued since 2007. Publishes original articles about the carried-out clinical, experimental and fundamental scientific works, reviews, lectures, descriptions of clinical cases, debatable materials, transfers of the foreign periodic medical press, and also auxiliary materials on all actual problems of reproductive medicine.

The main subject of the journal is focused on key questions of reproductive health, etiology and pathogenesis of various reproductive system diseases, features of their clinical picture.  And also to diagnostics and treatment of violations of a sexual differentiation, problems of fruitless marriage, auxiliary reproductive technologies, climacteric frustration...

The priority direction of the journal is acquaintance of a wide range of experts and healthcare providers with world tendencies of reproductive medicine, and also an assessment of emergence of the latest and perspective methods of treatment and prevention of diseases from a position of evidential medicine.

The journal:

acquaints readers with the original domestic and foreign researches reflecting development of world reproductive medicine;

issues the thematic numbers devoted to the separate directions (violations of formation of a floor, infertility, SPKYa, klimakteriya, replaceable hormonal therapy, pregnancy and diabetes...);

publishes the chronicle of the major international congresses and symposiums on reproductive medicine, and also the latest international and national clinical recommendations and consensuses;

is intended for scientists, obstetricians-gynecologists, endocrinologists, and also experts of all adjacent specialties, including urologists, general practitioners, family doctors, pediatricians, and other experts.

 The "Bulletin of Reproductive Health" journal is included in "The list of leading reviewed scientific journals and editions in which the main scientific results of theses on competition of a scientific degree of the doctor and the candidate of science", published by the Highest certifying commission of the Ministry of Education and Science of the Russian Federation in No. "Bulletin VAK" for 2012.

Federal Supervision Agency for Information Technologies and Communications registration ПИ № ФС77-26540 from 15.12.2006.


No announcements have been published.
More Announcements...

Current Issue

No 2 (2011)

Endometriosis: ways of the decision of a problem to the XXI century
Andreeva E.N., Gavrilova E.F.
Article is devoted an actual problem of gynecology – to an endometriosis which meets on the average at 12-50 % fertility women with chronic pelvic pain and/or barreness and at 5-35 % of women of reproductive age.Authors states results of researches of last years directed on working out of the new approach to treatment of patients with an endometriosis – complex therapy (antiviral preparations, hormonal therapy and immunomodulators) which application f or patients with an endometriosis extends time of remission of disease and increases frequency of approach of pregnancy.
Bulletin of Reproductive Health. 2011;(2):3-10
Embolization of uterine arteries is an effective and safe method of treating myoma of uterus
Sitkin I.I.
According to various authors myoma remains one of the most common diseases in women of reproductive age and is25-50% of all women over 30 years. Article contains a summary of interventional and modern method of treatment of uterine myoma by the uterine artery embolization. Detailed operation method reflected preand post-operative management of patients. Generalized international experience by the embolization on the impact on fertility and reproduction.
Bulletin of Reproductive Health. 2011;(2):11-17
Evolution of hormonal contraception
Uzhegova Z.A., Sviridonova M.A.
Today about 80 million women prevent unintended pregnancies using oral contraceptives all over the world. Oral contraceptives have been the most investigated medicines arriving on the market. The data about their potential benefits and risks for health are updated regularly, and thе tendency, maintenance is expected. Oral contraceptives are considered as the main large achievement in reproductive medicine because they provide essential health benefits, confirmed numerous researches; serious adverse effects were observed extremely seldom. Routine risk-factor revealing in potential users of oral contraceptives significantly decreases the conditions frequency of serious adverse effects.
Bulletin of Reproductive Health. 2011;(2):18-29
Outcomes of correction of metabolic risk at a polycystic ovary syndrome after the metformin treatment
Andreeva E.N., Sheremeteva E.V., Dedov I.I.
Polycystic ovary syndrome (PCOS) – a polymorphic disease with extremely variable clinical presentation and different phenotypes found in 5-10% of women of reproductive age. During the life of women with PCOS in 10-fold increased risk of developing type 2 diabetes, 7 times – hypertension and coronary heart disease, including myocardial infarction, more than2-fold increased risk of developing ovarian cancer, endometrial, breast cancer. Women with PCOS and if they have insulin resistance, central obesity, dyslipidemia, have the greatest risk of developing diabetes and cardiovascular disease. The use of metformin is potentially an effective method to overcome insulin resistance, improve hormonal, biochemical parameters and a possible reduction in cardiovascular risk in PCOS.
Bulletin of Reproductive Health. 2011;(2):35-41
Hyperprolactinemia and pregnancy:An Endocrine Society Clinical Practice Guideline, 2011
Dzeranova L.K., Bykanova N.S., Pigarova E.A.
Гиперпролактинемия является ведущей причиной бесплодия как у мужчин, так и у женщин. Впервые клинические рекомендации по диагностике и лечению гиперпролактинемии, были опубликованы в журнале Clinical Endocrinology в 2006 г. Эти рекомендации касались только гиперпролактинемии опухолевого генеза и не имели указания на уровень доказательности.В феврале 2011 г. в журнале The Journal of Clinical Endocrinology & Metabolism были опубликованы клинические рекомендации Международного эндокринологического общества по диагностике и лечению гиперпролактинемии ʹ Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. Shlomo Melmed, Felipe F. Casanueva, Andrew R. Hoffman, David L. Kleinberg, Victor M. Montori, Janet A. Schlechte, and John A. H. Wass. Cedars Sinai Medical Center (S.M.), Los Angeles, California 90048; University of Santiago de Compostela (F.F.C.), 15705Santiago de Compostela, Spain; VA Palo Alto Health Care System (A.R.H.), Palo Alto, California 94304; New York Univer-sity School of Medicine (D.L.K.), New York, New York 10016; Mayo Clinic Rochester (V.M.M.), Rochester, Minnesota 55905; University of Iowa (J.A.S.), Iowa City, Iowa 52242; and Churchill Hospital (J.A.H.W.),Headington, Oxford OX37LJ, United Kingdom [J ClinEndocrinol Metab, February 2011, 96(2):273-288].В работе экспертной группы подкомитета по разработке клинических руководств Эндокринологического общества использован доказательный подход к вопросам этиологии, диагностики и лечения гиперпролактинемии. Рассмотрены вопросы выбора лекарственных средств для лечения пролактином, показаний к их использованию и побочных эффектов. Отдельно выделены такие состояния, как лекарственно-индуцированная гиперпролактинемия, резистентные и злокачественные пролактиномы, а также особенности лечения пролактином во время беременности.
Bulletin of Reproductive Health. 2011;(2):42-44
News of reproductive medicine
Spiridonova M.A., Sazonova A.I.
Bulletin of Reproductive Health. 2011;(2):45-56

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies